Comparative Pharmacology
Head-to-head clinical analysis: PREDNISOLONE ACETATE versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREDNISOLONE ACETATE versus TEXACORT.
PREDNISOLONE ACETATE vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and NF-κB; suppresses immune response and inflammation.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
5-60 mg orally once daily or divided every 12-24 hours; dose depends on condition and severity. For acute exacerbations, 200-400 mg intramuscularly once.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (plasma); biological (tissue) half-life: 18-36 hours due to prolonged glucocorticoid receptor-mediated effects. Half-life prolonged in hepatic disease.
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal (fraction excreted unchanged: <1%); primarily hepatic metabolism to inactive glucuronide and sulfate conjugates eliminated renally and fecally. After oral administration, 12-15% of dose recovered in bile/feces as metabolites.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category D/X
Category C
Corticosteroid
Corticosteroid